20 Novemb The ManagASX Limit20 Bridge SSYDNEY Dear Mada

I attach anshareholder Yours faith

Peter J. NigCompany S pjn9169

ber 2017

ger Companted Street NSW 2000

am,

n address byrs present at

hfully

ghtingale Secretary

nies

0

PRESENT

y the Chairt today’s An

TATION TO

rman and annual Gener

O ANNUAL

a PowerPoinral Meeting

L GENERA

nt presentatwhich is co

E-mail: pW

AL MEETI

tion which onvened to b

Level 2, 6Syd

Tel: Fax:

pnightingale@Website: www

(19 p

ING

are to be dbe held at 1

66 Hunter Strdney NSW 2(61-2) 9300 3(61-2) 9221 6

@biotron.comw.biotron.com

pages by em

delivered to1.30 am.

reet 2000 344

6333 m.au m.au

mail)

o the

20 Novemb My Fellow

In recent wThe 36th adesigned tocurrent antchoice but of patients Company m This is the stepping stdeterminatisignificancdesired by Much has b Looking ahopportunitiportfolio of Importantlynow suppobeneficial a A disciplinpriority is tproduct. I would likproductive equally ded

ber 2017

w Shareholde

weeks, Biotroand final pao demonstrati-HIV treatto impatiendestined to

maybe, just

9th clinical tones alongion to deme of the Coshareholder

been achiev

head, we haies. Biotronf possibilitie

y, BIT225 iorts the belieagainst addi

ned and focuto retain fle

ke to take thefforts dur

dicated parti

ers

CH

on has takenatient in thate the Comtments. Anantly await fio live with th

maybe, ther

trial condug the clinicmonstrate soompany's plrs is by patie

ed during th

ave every ren should noes capable o

is only one ef that manyitional viral

used approaexibility in t

his opportunring the pasicipation an

HAIRMAN’

n a giant stehe Companympany's leaalysis of trianal results. his disease,re is light at

ucted by Biocal developmound scienclatform. Thently delive

he past 12 m

ason to be oot be vieweof delivering

of hundredsy opportunitargets.

ach to capitthe developm

nity to thanst12 monthsnd support.

S ADDRES

ep towards dy's Phase 2ad compounal data is, b Neverthele there is hot the end of

otron. The pment pathwce and provhe only wa

ering quality

months, as w

optimistic. d as a singlg sustainabl

s of Biotronities reside i

tal managemment of gro

nk our smals. I would

SS TO THE

demonstratin2 HIV trial nd, BIT225,by necessityess, we remope, and fora very long

previous eigway for BITven results

ay to achievy data from c

will be outlin

Close focusle asset come sharehold

n compoundin the Comp

ment is embowth opport

ll but dedicaalso like to

EW

E AGM

ng that eradcompleted

, benefits py, frustrating

main confidenthe thousan tunnel.

ght trials suT225. The add crede

ve the commclinical trial

ned in the C

s on our cormpany. Ouder value.

ds. A substpany's comp

bedded in otunities align

ated staff foo thank my

Level 2, 6Syd

Tel: Fax:

E-mail: info@Website: www

dication of Htreatment.

atients abovgly slow sont. For the nds of share

uccessfully pe latest triaence to ourmercial outls and suppo

CEO’s presen

re assets is pur diversity

tantial volumpound libra

our operatinned, of cour

or their detey fellow dire

66 Hunter Strdney NSW 2(61-2) 9300 3(61-2) 9221 6

@biotron.comw.biotron.com

HIV is possiThe trial w

ve and beyo we have li

many millieholders of

provided soual caps offr belief in comes that orting studie

ntation.

presenting noffers a str

me of evideary, likely to

ng model. Orse, to our l

ermination ectors for th

reet 2000 344

6333 m.au m.au

ible. was ond ittle ions this

und our the are

es.

new rong

ence o be

Our lead

and heir

In particular, I should single out Denis Wade for his enduring contribution and dedication to the Company since he joined the Board in 2010. For personal reasons, Denis steps down from the Board today. Denis' advice and insight have been of enormous value to me personally and to the entire Board. He departs with a mix of our regret and gratitude. I am relieved to report he won't be going far. Denis will retain an ongoing advisory role with the Company. I would now like to invite our CEO, Michelle Miller, to address the meeting.

Michael J. Hoy Chairman

Slide'tle

ForwardLookingStatements

Thispresenta'onmaycontainforward lookingstatementswithrespecttothefinancialcondi'on, resultsandbusinessachievements/performanceofBiotronLimited (ACN086399144)andcertainof theplansandobjec'vesofitsmanagement.Thesestatementsarestatementsthatarenot historicalfacts.Wordssuchas“should”,“expects”,“an'cipates”,“es'mates”,“believes”orsimilar expressions,astheyrelateto Biotron Limited, are intended to iden'fy forward lookingstatements. By their nature, forward lookingstatements involve risk and uncertainty because they reflect Biotron’s current expecta'ons andassump'onsastofutureeventsandcircumstancesthatmaynot proveaccurate.Thereisnoguaranteethat the expected events, trends or results will actually occur. Any changes in such assump'ons orexpecta'onscouldcauseactualresultstodiffermateriallyfromcurrentexpecta'ons.

InvestmentHighlights

•  Biotronisdesigning,developingandcommercialisingaplaUormofan'viraldrugswithanovelmodeofac'on–abletotargetawidevarietyofviralinfec'ons

•  Pipelineofprogramsinhighvalue,highneedmarkets•  Progressinclinicalleadprogram(BIT225)providesstrongvalida'onforen'replaUorm

BiotronLimited–SnapShot

BROADPLATFORMWITHNEWCLASSOFANTIVIRALDRUGS

HIV-1ERADICATION HBV&EARLYSTAGEPROGRAMSHEPATITISCVIRUS(HCV)

-  Targe'ngHIV-1inlong-livedreservoirs

-  Phase2trialinprogressduring2017;dosingcomplete

-  NewclassofHCVdrug

-  Phase2completed

-  SeekingpartnershipsinChina

-  Pipelineofearlystageprograms,including:

-  Hepa''sBvirus

-  Respiratoryviruses

-  Flaviviruses(e.g.Dengue)

ROBUSTCLINICALVALIDATION–COMPLETED8CLINICALTRIALSWITH

STRONGSAFETY&EFFICACYOUTCOMES

KeyAchievementsFY2017

•  CommencedPhase2clinicaltrialofBIT225andCombina'onAn'retroviralTherapy(cART)inFeb’17

•  FullyrecruitedinJuly‘17;DosingwithBIT225/placebocompleted;datapending

•  Demonstratedsignificantandacceleratedreduc'oninHIV-1viralloadfollowingaddi'onofBIT225inhumanisedmousestudyinFeb‘17

•  IndependentNaturepublica'onvalidatedBiotron’sapproachoftarge'ngHIV-1inmacrophagesasakeystepinHIV-1eradica'oninMay’17

•  AppointedLynxFinancialasCorporateAdvisorforChina–assis'ngwithexecu'ngHCVregionalpartneringstrategyinJune‘17

•  Raised$1.56millionviarightsissueinJune‘17

•  Received$1.6millionR&DtaxrefundinNov‘17(post-endofFY)

CommercialisaUon–KeyFocus

•  Threetac'calpriori'es:•  Partneringleadclinicalprogram-BIT225forHIV-1eradica'on

•  Partneringoneormorepreclinicalprograms–e.g.HBV

•  ExecutearegionallicensingdealinChina-HCVprogramremainsagreatopportunity

HIV-1EradicaUon

MarioStevensonScien.ficAmerican299,78-83(2008)

CurrentdrugsdonoteradicateHIV-1virus

WhyisHIV-1eradicaUonnecessary?•  Long-termhealthimplica'onse.g.HAND,immuneac'va'on,etc•  Costoftreatment

•  ~$20billionp.a.worldwide•  Majorburdenonhealthcaresystems

BIT225haspotenUaltobeusedincombinaUonwithotherdrugsto

eradicateHIV-1reservoirs

•  HIV-1remainshiddeninreservoirs,leadingtochronic,life-longinfec'on•  Invisibletobody’simmunedefenses•  Notsensi'vetoan'-HIV-1drugs

•  Newmodeofac'onsdrugsareneededtoeradicateorcureHIV-1infec'on

HIV-1EradicaUon:BIT225-009Trial

•  36HIV-1+ve,treatment-naïvesubjectscommencingART•  Randomised2:1(drug:placebo)

BIT225orplaceboaddedtoART

•  BIT225orplaceboaddedtoARTforfirst12weeksoftreatment•  Read-out

•  Impactonviruslevels;reduc'onofimmuneac'va'onmarkers•  Fullyrecruited;completeddosingwithBIT225/placebo;infollow-upperiod(ARTalone)

HIV-1EradicaUon:BIT225-009Trial

•  FullyrecruitedJuly;lastpa'ent,lastdoseinmid-October

•  Threemonthfollow-upperiodpost-dosingwithBIT225/placebo

•  Addi'onalsamplescollectedfrompa'entsthroughoutthisnext3monthperiod

•  Post-triallaboratoryanalysesonsamplesfromtreatmentperiodareinprogress:

•  VirologicalOutcomes

•  ImmunologicalOutcomes

•  Post-dosingsampledataalsorequiredtocompletetheanalyses

•  E.g.Anyreboundorchangeinparametersoncedrugceased?

•  Alldataisnecessarytodetermineoutcomeofthetrial

CommercialisaUon:BIT225HIV-1EradicaUon

•  Severalpharmaceu'calcompanieshaveac'veHIV-1“Cure”Programs•  Iden'fiedandqualifiedpoten'alpartners

•  Posi'veoutcomes–BIT225clinicaltrial-keytoprogressingcommercialisa'ondiscussions

•  Poten'alpartnershavedefinedtheirsuccesscriteria–wearealigned!

•  Communica'ngtrialdataassoonasavailable

•  Followupmee'ngswithpoten'alpartnerscon'nue

CommercialisaUon:PreclinicalPrograms–HBV

•  Hepa''sBvirus(HBV)therapeu'cspacehassignificantinterestfrompharma&biotechcompanies

•  Biotron’sHBVprogramiselici'ngearlyinterestfrompoten'alpartners

•  Invitrodataonseveralcandidatecompoundsincludesevidenceofreduc'onofindustryrecognisedmarkers

•  Novelmechanismisveryasrac'veincombina'onapproachestotreatmentofHBV

•  ExpandsBiotron’spartneringopportuni'es–poten'alforearlystageco-development/collabora'onagreement

CommercialisaUon:RegionalLicensing–China,HCVProgram

•  ThenewHCVdrugs(e.g.Solvadi)maycausereac'va'onofHBVinHCV/HBVcoinfectedpa'ents

•  ResultedinUSFDA“BlackBox”WarningonnewHCVdrugs

•  30millionHCV-infectedpeopleinChina,comparedto3-5millioninUSA

•  93millionchronicallyinfectedwithHBVinChina,comparedto2.2millioninUSA

•  HighHCV/HBVco-infec'onrateinChina(es'matedtobe10million)

•  Reac'va'onofHBVinpeopleundergoingHCVtreatmentwiththesenewHCVdrugshaspoten'altobeamajorhealth&economicissueinChina

•  BIT225hasbeenshowninclinicaltrialstosignificantlyimproveclinicaloutcomeinHCVGT1-infectedpa'entsincombina'onwithInterferon&Ribavirin(IFN/RBV)

•  IFN/RBVhaveseveralpoten'aladvantagesovernewHCVdrugsinsomesevngs

•  IFN/RBVissignificantlycheaperthanthenewHCVdrugs

•  HBVreac'va'onislesscommonandlesssevereinHCV/HBVco-infectedpa'entswithIFN/RBV

•  Seekingpartnershipsforcommercialisa'onofBIT225forthetreatmentofHCVinChina

•  AppointedaShanghai-basedcorporateadvisorwithextensiveexperienceincross-border

transac'onsinthehealthcarespace

•  Developedawellqualifiedprospectlist

•  Presentedtopoten'allicensees–allwithcapacitytofinalisecommercialdevelopmentand

launchofBIT225inChina

•  Discussionsareon-going

CommercialisaUon:RegionalLicensing–China,HCVProgram

UnlockingValueforOtherVirusTargets

Libraryofcompoundsdesignedtotargetviroporinsfoundinsomeviruses:Ini'ally>250compoundsdesignedandsynthesised;librarynow~350OTHER“HITS”INLIBRARYinclude:•  InfluenzaAandB•  Hepa''sBvirus(HBV)•  Coronaviruses(IncludingSARS)•  Epstein-Barrvirus(EBV)•  Zikavirus•  others

X-axis:compoundIDY-axis:virusZ-axis:strengthofhit

UnlockingValueforOtherVirusTargetsBiotron’sViroporinapproachenablesthetarge'ngofawiderangeofviraldiseases;examplesinclude:•  RespiratoryVirusessuchasRespiratorySyncy'alVirus(RSV),Influenza,&Coronaviruses(leadingcauseof

“commoncold”)•  FlavivirusessuchasZikaVirusandDengue•  TransplantvirusessuchasBKvirus•  EpsteinBarrvirus(EBV)-par'cularinterestinAsiawhereitiscausa'veagentofNasopharyngeal

Carcinoma

Biotron’sViroporinplacormhasthepotenUaltobecomeanimportanttoolinthe

developmentofanUviraltherapies

PotenUalforestablishingearlystagecollaboraUonswithpharmaceuUcalcompaniesuUlisingBiotron’sapproach

Summary

•  HIVEradicaUon•  Engagedwiththerightpoten'alpartners•  Wai'ngfordatafromtrialbutcon'nuetoengagewithpharma

•  PreclinicalPrograms•  HBVhaspromiseasapreclinicalcandidateforjointdevelopment.HBVtherapeu'cspaceisveryhot.•  BIT225resultsvalidatetheplaUorm;poten'altofacilitatefundeddevelopmentsbypartnersfor

“other”viraldiseases•  RegionalLicensing

•  HCVinChinaremainsasignificantdevelopmentopportunity–“cost-conscious”marketcombinedwiththehighrateofco-infec'onHCV&HBVrequiresdifferentapproachthanusedintheUSA

Successinanyorallofthesestrategieswillbea“companymaker”increasingthevaluefor

Biotronstakeholders